Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COVID-19

Neutralizing antibody response in mild COVID-19

Subjects

This preprint reports robust induction of SARS-CoV-2-specific neutralizing antibodies in 94% of 175 patients with clinically mild COVID-19 within 2 weeks of symptom onset. Compared with young patients, middle-aged and older patients in this cohort had higher titres of neutralizing and binding antibodies. As older patients are generally considered at greater risk of severe disease, the robust humoral responses in this cohort may explain their apparent protection. Of note, 10 of 175 patients recovered without developing detectable neutralizing antibody titres, suggesting that antiviral binding antibodies and cellular immune responses can both result in convalescence. Longitudinal observations in addition to stringent clinical and immunological characterization are needed to further assess the specificity and relative contribution to protection of neutralizing antibodies against SARS-CoV-2.

References

Original article

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Verena van der Heide.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

van der Heide, V. Neutralizing antibody response in mild COVID-19. Nat Rev Immunol 20, 352 (2020). https://doi.org/10.1038/s41577-020-0325-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-020-0325-2

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing